Drug Profile
Research programme: T-cell anticancer therapies - eXtellia therapeutics/San Raffaele University
Latest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator eXtellia Therapeutics; Ospedale San Raffaele
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Gene transference; T-cell receptor antigen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute myeloid leukaemia; Cancer; Haematological malignancies
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in Italy
- 28 Jun 2022 No recent reports of development identified for research development in Haematological-malignancies in Italy
- 28 Jul 2021 No recent reports of development identified for research development in Cancer in Italy